Mereo BioPharma (MREO) - חוב להון עצמי

Mereo BioPharma (MREO) generates revenue by creating unique therapies for rare pathologies, including osteogenesis imperfecta, relying on insurance reimbursements. The company minimizes late-stage testing costs through global alliances while developing a portfolio of genetic and oncological drugs. The price action on this chart, where the indicator equals 0.04, illustrates financial resilience amid anticipation of the FDA verdict on setrusumab.

Defensive assets are selected based on the criterion of minimal debt load. Mereo BioPharma (MREO) meets this principle due to the resilience of the orphan drug niche and the support of major partners. This total debt-to-equity calculation measures the proportion of borrowed funds relative to own resources. The coefficient determines the level of financial leverage and bankruptcy risk. The downward trend on this chart confirms the strengthening of the business's solvency.